The earnings call presented a mixed picture. On the positive side, Hypera Pharma reported significant sell-out growth, successful product launches, and strong cash flow. The company's sustainability efforts were also recognized. However, these were offset by a decline in net revenue and gross margins due to the working capital optimization strategy. Additionally, there were challenges in the generics market. Overall, the sentiment is balanced, with both positive achievements and significant challenges.

Company Guidance

In the Hypera Pharma earnings call for Q4 2024, the company provided guidance highlighting significant growth metrics and strategic initiatives. Sell-out growth was reported at 9% for the year, with a notable 26% increase in the institutional non-retail market and an 8% rise in the retail market. Despite these gains, net revenue decreased by 6% to BRL7.4 billion, primarily due to a working capital optimization strategy initiated in Q3 2024. This strategy aims to enhance operational cash flow by reducing client inventories and account receivable days, achieving about 80% of the intended adjustments with an average sales term of 70 days. The company invested over BRL2.3 billion in marketing, innovation, and production capacity, including BRL1.3 billion in marketing and BRL550 million in research and innovation, with over 50 new product launches. EBITDA margin stood at 28%, with a net income reduction of 19% due to lower operational leverage. Additionally, Hypera Pharma maintained a strong focus on sustainability, being recognized in indices like FTSE4Good and B3 IDIVERSA. The company anticipates normalizing operations and combining sustainable growth with better returns on invested capital by May 2025.

Sell-out Growth in 2024

Hypera Pharma's sell-out increased by 9% in 2024, with a significant 26% growth in the institutional non-retail market and 8% in the retail market.

Successful Product Launches

The company launched over 50 new products in 2024, including significant line extensions in consumer health, skincare, cardiology, CNS, and respiratory segments.

Record Operational Cash Flow

Hypera Pharma achieved its highest operational cash flow in history, exceeding BRL2.5 billion, reflecting improvements in capital and working capital investments.

Sustainability and Governance Recognition

The company was recognized in the FTSE4Good and S&P Global Sustainability Yearbook, highlighting its commitment to sustainable practices and corporate governance.

Working Capital Optimization Progress

Hypera Pharma advanced its working capital optimization strategy, achieving 80% of the planned adjustments by early 2025, improving operational cash generation.

Hypera SA (HYPMY) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

HYPMY Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Oct 28, 2025	2025 (Q3)	- / -	0.107	―	―	―
Aug 06, 2025	2025 (Q2)	- / 0.12	0.149	-20.13% (-0.03)
Apr 23, 2025	2025 (Q1)	- / -0.04	0.125	-130.40% (-0.16)
Mar 20, 2025	2024 (Q4)	- / 0.02	0.098	-77.55% (-0.08)
Nov 13, 2024	2024 (Q3)	- / 0.11	0.162	-33.95% (-0.06)
Jul 25, 2024	2024 (Q2)	- / 0.15	0.161	-7.45% (-0.01)
Apr 26, 2024	2024 (Q1)	- / 0.13	0.103	21.36% (+0.02)
Mar 13, 2024	2023 (Q4)	- / 0.10	0.129	-24.03% (-0.03)
Oct 26, 2023	2023 (Q3)	- / 0.16	0.14	15.71% (+0.02)
Jul 27, 2023	2023 (Q2)	- / 0.16	0.147	9.52% (+0.01)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

HYPMY Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Aug 06, 2025	$4.56	$4.40	-3.51%
Apr 23, 2025	$3.70	$4.11	+11.08%
Mar 20, 2025	$3.38	$3.48	+2.96%
Nov 13, 2024	$3.45	$3.45	0.00%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Hypera SA (HYPMY) report earnings?

Hypera SA (HYPMY) is schdueled to report earning on Oct 28, 2025, After Close (Confirmed).

What is Hypera SA (HYPMY) earnings time?

Hypera SA (HYPMY) earnings time is at Oct 28, 2025, After Close (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is HYPMY EPS forecast?

Currently, no data Available

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing